Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis. 1992

M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
Clinique de Réanimation des Maladies Infectieuses, Hôpital Bichat-Claude Bernard, Paris, France.

We evaluated the diffusion of cefpirome into the cerebrospinal fluid (CSF) of 25 patients with bacterial meningitis or ventriculitis who were receiving conventional antibiotic treatment. A single cefpirome dose of 2 g was infused at day 2-3 after the onset of therapy. Concentrations of cefpirome in serum and CSF obtained at 2, 4, 8 or 12 h after the infusion were determined by high-performance liquid chromatography. The mean (+/- S.E.M.) concentrations of cefpirome in CSF ranged from 2.26 +/- 1.16 to 4.17 +/- 0.83 mg/L. These concentrations were higher than the MBCs for the pathogens usually responsible for bacterial meningitis.

UI MeSH Term Description Entries
D008297 Male Males
D008586 Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111) Meningitis, Streptococcus pneumoniae,Experimental Pneumococcal Meningitis,Meningitis, Pneumococcal, Experimental,Meningitis, Pneumococcal, Penicillin-Resistant,Meningitis, Pneumococcal, Recurrent,Experimental Pneumococcal Meningitides,Meningitides, Streptococcus pneumoniae,Meningitis, Experimental Pneumococcal,Pneumococcal Meningitides,Pneumococcal Meningitides, Experimental,Pneumococcal Meningitis,Pneumococcal Meningitis, Experimental,Streptococcus pneumoniae Meningitides,Streptococcus pneumoniae Meningitis
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004058 Diffusion The tendency of a gas or solute to pass from a point of higher pressure or concentration to a point of lower pressure or concentration and to distribute itself throughout the available space. Diffusion, especially FACILITATED DIFFUSION, is a major mechanism of BIOLOGICAL TRANSPORT. Diffusions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000097572 Cefpirome A fourth-generation cephalosporin antibacterial agent. Appears to be more active in vitro against Staphylococci, some Enterococci, some ENTEROBACTERIACEAE, and PSEUDOMONAS AERUGINOSA.Cefpirome has a pyridinium group attached to C-3 position of its cephalosporin core. Cefpirome Sulfate,3-((2,3-cyclopenteno-1-pyridinium)methyl)-7-(2-syn-methoximino-2-(2-aminothiazole-4-yl)acetamido)ceph-3-em-4-carboxylate,Cefrom,HR 810,HR-810,810, HR,Sulfate, Cefpirome
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
December 1984, Presse medicale (Paris, France : 1983),
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
May 1985, Pathologie-biologie,
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
June 1989, Antimicrobial agents and chemotherapy,
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
April 1980, Antimicrobial agents and chemotherapy,
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
February 1984, Presse medicale (Paris, France : 1983),
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
January 1986, Infection,
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
January 1983, Antimicrobial agents and chemotherapy,
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
July 1985, Antimicrobial agents and chemotherapy,
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
January 1996, Neurologia i neurochirurgia polska,
M Wolff, and P Chavanet, and A Kazmierczak, and A Pechinot, and C Dematons, and H Portier, and B Lenfant
January 1971, Therapie,
Copied contents to your clipboard!